Search results
Springfield man says his ulcerative colitis was under control, then Cigna changed his meds
Springfield News-Leader via Yahoo News· 2 years agoNearly a year-and-a-half ago, Mark Hall's ulcerative colitis was "in remission" and he was getting...
Johnson & Johnson (JNJ) Down 2.2% Since Last Earnings Report: Can It Rebound?
Zacks via Yahoo Finance· 1 year agoIt has been about a month since the last earnings report for Johnson & Johnson (JNJ). Shares have...
J&J (JNJ) Beats on Q2 Earnings & Sales, Lowers 2022 Guidance
Zacks via Yahoo Finance· 2 years agoJohnson & Johnson’s JNJ second-quarter 2022 earnings came in at $2.59 per share, which beat the...
J&J (JNJ) Q1 Earnings Beat Estimates, Sales Miss, MedTech Soft
Zacks via Yahoo Finance· 2 months agoJohnson & Johnson’s JNJ first-quarter 2024 earnings came in at $2.71 per share, which beat the Zacks...
J&J (JNJ) Q2 Earnings & Sales Top, '23 View Upped, Stock Jumps
Zacks via Yahoo Finance· 10 months agoJohnson & Johnson’s JNJ second-quarter 2023 earnings came in at $2.80 per share, which beat the...
Insurers are bypassing hospitals and delivering pricey chemo and other infusion drugs via...
Fortune via Yahoo Finance· 11 months agoHealth insurers and medical providers are battling over who should supply high-cost infusion drugs...
Why Is Johnson & Johnson (JNJ) Down 0.2% Since Last Earnings Report?
Zacks via Yahoo Finance· 3 months agoIt has been about a month since the last earnings report for Johnson & Johnson (JNJ). Shares have...
J&J (JNJ) Beats Q3 Earnings & Sales Estimates Post Spin-Off
Zacks via Yahoo Finance· 8 months agoJohnson & Johnson’s JNJ third-quarter 2023 earnings came in at $2.66 per share, which beat the Zacks...
A Challenger to J&J's Top Blockbuster Is on the Way. Here's What You Need to Know.
Motley Fool· 1 year agoWhen you think of Johnson & Johnson (NYSE: JNJ), you may think of shampoo and Band-Aids. In fact,...
Johnson & Johnson Beats Q3 Estimates Led By Strength From Cancer, Crohn's Disease Drugs, Tightens...
Benzinga via Yahoo Finance· 2 years agoJohnson & Johnson (NYSE: JNJ) has reported Q3 FY22 adjusted earnings of $2.55 per share, down 1.9%...